Discover the Latest in Biomedical Research Innovation

Your treated and control wells started at different confluence, so comparing endpoints with a plain ANOVA measures your treatment effect plus the head start. ANCOVA fixes that by adjusting for a continuous covariate, and usually buys power too. This step-by-step ANCOVA protocol runs 24 numbered steps from covariate choice through reporting, with the assumption checks in the order they need to happen, including the parallel-slopes test most people skip.

When medical residents were surveyed on interpreting a p-value, 88% were confident they understood it and 100% got it wrong. That gap is why p-value mistakes survive peer review: nobody thinks they're making one. This piece covers the five most common errors in biomedical papers, several measured at scale in real journals: the inverse probability fallacy, the replication fallacy, 'trending toward significance', p-hacking, and treating 0.05 as a bright line.

Walk into most labs and you'll find a multi-seat GraphPad Prism license that only one or two people can actually use. Prism is powerful, but its learning curve takes months, so the license sits idle while everyone waits on the lab's 'stats person.' This piece makes the case for a different GraphPad Prism alternative: Sophie, the AI you just talk to. Describe your experiment in plain English and it picks the right test, runs it, and explains the result.

A small p-value tells you a difference is probably real, not that it's big enough to matter. Statistical significance asks whether an effect is distinguishable from noise; biological significance asks whether it's large enough to change a cell, a patient, or a conclusion. Because the p-value shrinks as your sample grows, a big enough study can stamp p < 0.05 on a difference that means nothing. Here's why, with real examples, and what to report instead: effect size and confide